The effect of different preparations of hormone therapy on tumor necrosis factor-α levels in women with surgical menopause

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Gynecological Endocrinology

• Publication date

  2008-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/09513590701718307PMID 18210330
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women

  2006cited by this paper
• Chronic Tumor Necrosis Factor-&agr; Inhibition Enhances NO Modulation of Vascular Function in Estrogen-Deficient Rats

  2005influential reference
• Relation of high-sensitivity C-reactive protein, interleukin-6, tumor necrosis factor-alpha, and fibrinogen to abdominal adipose tissue, blood pressure, and cholesterol and triglyceride levels in healthy postmenopausal women.

  2005cited by this paper
• Acute changes in circulating hormones in older patients with impaired ventricular function undergoing on-pump coronary artery bypass grafting

  2005cited by this paper
• The relationship between testosterone and molecular markers of inflammation in older men.

  2005cited by this paper
• Tumor necrosis factor-alpha inhibits endothelial nitric-oxide synthase gene promoter activity in bovine aortic endothelial cells.

  2004cited by this paper
• National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section

  2004cited by this paper
• NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-α

  2004cited by this paper
• NAD(P)H oxidase mediates the endothelial barrier dysfunction induced by TNF-alpha.

  2004cited by this paper
• Association of lipoproteins with cytokines and cytokine receptors in heart failure patients. Differences between ischaemic versus idiopathic cardiomyopathy.

  2003cited by this paper
• Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

  2002cited by this paper
• Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal.

  2002cited by this paper
• Changes in proinflammatory cytokine activity after menopause.

  2002cited by this paper
• Effect of Medroxyprogesterone Acetate on Vascular Inflammatory Markers in Postmenopausal Women Receiving Estrogen

  2002cited by this paper
• Tibolone: what does tissue specific activity mean?

  2001cited by this paper
• Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women.

  2001cited by this paper
• Postmenopausal changes in serum cytokine levels and hormone replacement therapy.

  2001influential reference
• Bone-Resorbing Cytokines from Peripheral Blood Mononuclear Cells after Hormone Replacement Therapy: A Longitudinal Study

  2001cited by this paper
• Testosterone deficiency in women.

  2001cited by this paper
• Estrogen Treatment Down-Regulates TNF-α Production and Reduces the Severity of Experimental Autoimmune Encephalomyelitis in Cytokine Knockout Mice1

  2001cited by this paper
• The effect of 17beta-estradiol on production of cytokines in cultures of peripheral blood.

  2001cited by this paper
• Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure.

  2000cited by this paper
• The expression of transforming growth factor-β and interleukin-1ß mRNA and the Response to 1,25 (OH)2D3, 17ß-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro

  1999cited by this paper
• The expression of transforming growth factor-beta and interleukin-1beta mRNA and the response to 1,25(OH)2D3' 17 beta-estradiol, and testosterone is age dependent in primary cultures of mouse-derived osteoblasts in vitro.

  1999cited by this paper
• IL-6 expression by oral fibroblasts is regulated by androgen.

  1998cited by this paper
• Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

  1998cited by this paper
• Estrogen Deficiency Increases the Ability of Stromal Cells to Support Murine Osteoclastogenesis via an Interleukin-1and Tumor Necrosis Factor-mediated Stimulation of Macrophage Colony-stimulating Factor Production*

  1996cited by this paper
• Tumor necrosis factor: a pleiotropic cytokine and therapeutic target.

  1994cited by this paper
• Estrogen modulates the expression of tumor necrosis factor alpha mRNA in phorbol ester-stimulated human monocytic THP-1 cells.

  1994cited by this paper
• Oestradiol inhibits the release of tumour necrosis factor but not interleukin 6 from adult human osteoblasts in vitro

  1992cited by this paper
• Effect of surgical menopause and estrogen replacement on cytokine release from human blood mononuclear cells.

  1991cited by this paper
• Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study.

  1991cited by this paper
• Estrogen inhibits release of tumor necrosis factor from peripheral blood mononuclear cells in postmenopausal women

  1990cited by this paper
• Tumor necrosis factor alpha: a multifaceted peptide hormone.

  1989cited by this paper
• The effect of estrogen treatment on plasma concentrations of steroid hormones, gonadotropins, prolactin and sex hormone-binding globulin in post-menopausal women.

  1985cited by this paper

• The effect of tibolone treatment on lipid profile in women: a systematic review and dose-response meta-analysis of randomized controlled trials.

  2021cites this paper
• Relationship between circulating tumor necrosis factor system and bone mass before and after estrogen plus progestogen therapy

  2009cites this paper